High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effectiveness of a particular combination of drugs used to treat cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Chicago
• Treatments: Cytarabine; Etoposide; Etoposide phosphate; Mitoxantrone

Criteria

Inclusion Criteria:

• Patients must have received cytotoxic chemotherapy,radiation,or a drug known to affect the properties of DNA or cell growth for some condition other than acute myeloid leukemia prior to diagnosis.

• Patients must have t-MDS/t-AML

• To be eligible for allogeneic transplantation, patients must have a suitable donor who is HLA compatible.

• Patients must be over the age of 10.

• Patients must be reviewed and discussed at the Leukemia and Transplant Conferences of the Section of Hematology/Oncology.

Exclusion Criteria:

• Patients must not have any other serious medical condition(e.g.uncontrolled or severe cardiovascular disease, diabetes, pulmonary disease, or infection)

• Psychiatric condition which would prevent compliance or possibly be worsened by treatment